瑞波西汀与马普替林治疗伴有焦虑症状的抑郁症

目的探讨瑞波西汀和马普替林治疗伴有焦虑症状的抑郁症的疗效与安全性。方法将69例伴有焦虑症状的抑郁症患者随机分为瑞波西汀组35例和马普替林组34例。观察6周，于治疗前和治疗后1、2、4及6周末采用汉密尔顿抑郁量表及汉密顿焦虑量表评定其疗效，用不良反应量表评定其不良反应。结果瑞波西汀组的显效率为80％，马普替林组的显效率为79％，瑞波西汀组不良反应相对较少。结论瑞波西汀治疗抑郁症疗效较好，且起效快，不良反应少。

Fluvoxamine and maprotiline in the treatment of depression and anxiety

Objective To investigate the efficacy and safety of fluvoxamine in the treatment of patients with refractory depression and anxiety. Methods Sixty - nine patients with refractory depression and anxiety were randomly assigned to 6 weeks treatment with fluvoxamine （n = 35 ）or maprotiline （n = 34 ） and changes from baseline in the Hamilton Rating Scale for Depression（ HAMD - 17 ） , total scores of the two groups, and Treatment Emergent Symptom Scale （TESS）were compared at 1 week before treatment and 1, 2, 4, 6 weeks after treatment. Results The significant efficacy rates of fluvoxamine group was 78%, while that was 75% in the maprotiline group. There were less side effects in the fluvoxamine group than maprotiline group. Conclusions Fluvoxamine is better than maprotiline in the treatment of refractory depression and anxiety, It shows better efficacy and less side effects. It is beneficial to improve the herapeutie compliance of depressive natients.